— Amy Killelea, an attorney and the director of health systems integration at the National Association of State and Territorial Apprenticeship Directors (NASTAD), which represents officials who administer HIV programs, speaking to Health Plan Week about insurers' coverage policies for Gilead's HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate).
Wednesday, September 6, 2017
Quote of the Day
"For PrEP,
we have seen an uptick in some [Truvada] access restrictions, but the
UnitedHealthcare requirements were the most egregious....[There have been]
numerous complaints filed under the ACA's non-discrimination protections citing
discriminatory plan designs that effectively bar people living with HIV from
access to lifesaving medications."
— Amy Killelea, an attorney and the director of health systems integration at the National Association of State and Territorial Apprenticeship Directors (NASTAD), which represents officials who administer HIV programs, speaking to Health Plan Week about insurers' coverage policies for Gilead's HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate).
— Amy Killelea, an attorney and the director of health systems integration at the National Association of State and Territorial Apprenticeship Directors (NASTAD), which represents officials who administer HIV programs, speaking to Health Plan Week about insurers' coverage policies for Gilead's HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment